NCT02806414View on ClinicalTrials.gov

Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

July 31, 2019

Study Completion Date

May 31, 2021

Conditions
Rosacea
Interventions
DRUG

Ivermectin

Trial Locations (1)

92122

UCSD Division of Dermatology, San Diego

Sponsors

Collaborators (1)

Galderma R&D
All Listed Sponsors
collaborator

Galderma R&D

INDUSTRY

lead

University of California, San Diego

OTHER

NCT02806414 - Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation. | Biotech Hunter | Biotech Hunter